Garry Ph.D. Nolan Sells 1,800 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock

Akoya Biosciences, Inc. (NASDAQ:AKYAGet Rating) Director Garry Ph.D. Nolan sold 1,800 shares of the stock in a transaction on Monday, September 12th. The stock was sold at an average price of $13.30, for a total value of $23,940.00. Following the sale, the director now owns 631,093 shares of the company’s stock, valued at $8,393,536.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Garry Ph.D. Nolan also recently made the following trade(s):

  • On Friday, September 9th, Garry Ph.D. Nolan sold 22,191 shares of Akoya Biosciences stock. The stock was sold at an average price of $13.31, for a total value of $295,362.21.

Akoya Biosciences Trading Up 1.0 %

Akoya Biosciences stock opened at $12.77 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.55 and a quick ratio of 3.16. The company has a market capitalization of $480.02 million, a price-to-earnings ratio of -7.56 and a beta of 0.93. Akoya Biosciences, Inc. has a one year low of $8.02 and a one year high of $21.21. The company’s fifty day moving average price is $13.55 and its two-hundred day moving average price is $11.71.

Akoya Biosciences (NASDAQ:AKYAGet Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.13). The business had revenue of $17.89 million for the quarter, compared to analyst estimates of $16.93 million. Akoya Biosciences had a negative return on equity of 55.41% and a negative net margin of 98.08%. During the same period in the previous year, the company earned ($0.20) earnings per share. On average, analysts forecast that Akoya Biosciences, Inc. will post -1.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on AKYA. BTIG Research increased their target price on shares of Akoya Biosciences to $20.00 in a research report on Monday, August 15th. Piper Sandler increased their target price on shares of Akoya Biosciences from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 17th. Finally, TheStreet raised shares of Akoya Biosciences from a “d” rating to a “c-” rating in a research report on Thursday, July 21st.

Institutional Investors Weigh In On Akoya Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp grew its position in shares of Akoya Biosciences by 10.2% in the second quarter. State Street Corp now owns 200,936 shares of the company’s stock valued at $2,582,000 after purchasing an additional 18,645 shares during the last quarter. Millennium Management LLC grew its position in shares of Akoya Biosciences by 6.1% in the second quarter. Millennium Management LLC now owns 718,063 shares of the company’s stock valued at $9,227,000 after purchasing an additional 41,261 shares during the last quarter. Sei Investments Co. acquired a new stake in shares of Akoya Biosciences in the second quarter valued at about $682,000. American International Group Inc. grew its position in shares of Akoya Biosciences by 10.8% in the second quarter. American International Group Inc. now owns 7,381 shares of the company’s stock valued at $95,000 after purchasing an additional 718 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Akoya Biosciences by 11.6% in the second quarter. Northern Trust Corp now owns 117,582 shares of the company’s stock valued at $1,511,000 after purchasing an additional 12,198 shares during the last quarter. 34.54% of the stock is owned by institutional investors and hedge funds.

About Akoya Biosciences

(Get Rating)

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

See Also

Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.